ADC Therapeutics (ADCT) Q4 2025 earnings review
A Bridge to 2026: Cash Secured, M&A Hurdle Lowered, Waiting on Data
ADC Therapeutics reported a deceptively strong Q4 with ZYNLONTA net product revenue jumping 36% YoY to $22.3 million. However, management explicitly stated this was due to customer ordering variability, while underlying demand remains 'broadly stable' (stagnant). The real story is the balance sheet and strategic positioning. Following aggressive 2025 restructuring and $150.8M in PIPE financings, cash is secured into 2028. Crucially, the company renegotiated its HealthCare Royalty agreement, dropping a massive change-of-control penalty from $750M to $150M—a flashing signal that ADCT is making itself an acquisition target ahead of its critical LOTIS-5 and LOTIS-7 data readouts in 2026.
🐂 Bull Case
The renegotiation of the HealthCare Royalty agreement drastically reduces the change-of-control payment from an unpalatable $750M to a manageable $150M through 2027. This provides massive strategic flexibility and makes the company highly acquirable.
Ending the year with $261.3M in cash guarantees the company can fund operations at least into 2028. This easily bridges the gap to the critical LOTIS-5 (Q2 2026) and LOTIS-7 (YE 2026) data readouts without the threat of near-term dilutive equity raises.
🐻 Bear Case
Stripping away the Q4 'ordering variability', ZYNLONTA's underlying 3L+ DLBCL monotherapy demand is not growing. The company is completely dependent on future label expansions to drive meaningful revenue.
Even if the LOTIS-5 data in Q2 2026 is stellar, sBLA submissions and compendia inclusions are not expected until H1 2027. Investors face a long waiting period before seeing actual revenue acceleration.
⚖️ Verdict: ⚪
Neutral. The base commercial business remains uninspiring, but management has masterfully executed on the financial side. By slashing costs, raising capital, and removing the $750M change-of-control penalty, they have perfectly positioned ADCT as a clean, binary play on the upcoming 2026 LOTIS trial readouts.
Key Themes
Strategic Restructuring Lowers M&A Hurdle
In a massive strategic move, ADCT amended its royalty agreement with HealthCare Royalty. Previously, an acquirer would face a $750M change-of-control payment. That has now been slashed to $150M through 2027 (and $200M thereafter) in exchange for 9.8M warrants at $3.81/share. This is a massive driver for the stock, as it immediately makes the company a viable acquisition target for larger oncology players looking for a de-risked DLBCL asset.
LOTIS-7: The 'Best-in-Class' Bispecific Combination
The company's primary technological innovation driver is the LOTIS-7 Phase 1b trial, evaluating ZYNLONTA in combination with Roche's bispecific antibody, glofitamab (COLUMVI). Updated data reported in December 2025 demonstrated a stunning 89.8% best overall response rate (ORR) and a 77.6% complete response (CR) rate across 49 patients. Management is accelerating this program to pursue a compendia listing, which could bypass a lengthy FDA approval process and open a $500M-$800M peak revenue opportunity.
Disciplined Cost Controls Extending Runway
Management has successfully executed its June 2025 restructuring plan (which included closing the UK facility and reducing the workforce by 30%). Q4 R&D expenses decelerated to $18.2M (down from $27.1M a year ago), and full-year adjusted operating expenses fell by $12.4M. This fiscal discipline, paired with the 2025 PIPEs, guarantees survival into 2028.
Revenue Spike Contradicts Flat Demand Narrative
While headline Q4 product revenue surged 36% YoY to $22.3M, management explicitly warned this was driven by 'customer ordering' variability. The underlying demand is 'broadly stable'. This is a red flag: it means the core 3L+ DLBCL monotherapy market has plateaued at roughly $16M-$18M per quarter, and Q4 was essentially an inventory pull-forward rather than a true sales breakout.
Timeline Push-Outs for Label Expansion
The timelines for revenue inflection are decelerating. LOTIS-5 topline data is now expected in Q2 2026 (previously guided as 1H 2026), and the associated sBLA submission and compendia inclusions are slated for H1 2027. Investors must endure a long period of stagnant base revenues before the new indications can be monetized.
Highly Competitive Macro Landscape in DLBCL
The treatment landscape for diffuse large B-cell lymphoma (DLBCL) is evolving rapidly with the introduction of new bispecifics and CAR-T therapies. If competitors establish dominant combinations in the 2nd-line setting before ZYNLONTA secures its LOTIS-5 (rituximab combo) or LOTIS-7 (glofitamab combo) approvals, market penetration could be severely hampered.
Other KPIs
Reversing. A massive improvement from the $30.7M net loss in 24Q4. However, investors must look under the hood: this was heavily aided by a $21.7M non-cash cumulative catch-up adjustment gain related to their deferred royalty obligation. Adjusted net loss, which strips out these accounting anomalies, was $13.5M.
Stable and strong. Up from $250.9M at the end of 2024, fortified by $150.8M in net proceeds from two 2025 PIPE financings. Total assets sit at $323.1M against $508.9M in liabilities, highlighting the heavily levered structure (driven by deferred royalty obligations), but the cash balance itself is highly protective.
Guidance
Stable timeframe, slightly more specific than the previous '1H 2026' guidance. This trial evaluates ZYNLONTA in combination with rituximab for 2L+ DLBCL. Positive results are the mandatory prerequisite for the planned H1 2027 sBLA submission.
Stable. The trial remains ongoing at the 150 µg/kg dose. The company plans to share the full dataset at a medical meeting by the end of 2026, which will dictate the subsequent regulatory and compendia strategies.
Stable. Management reaffirmed that the current cash balance of $261.3M is sufficient to fund operations past all major clinical catalysts in 2026 and through the potential launch of expanded indications in 2027.
Key Questions
Q4 Ordering Variability
You noted the Q4 revenue jump to $22.3M was driven by customer ordering variability. Should we expect a corresponding inventory destocking effect that will pull Q1 2026 revenues significantly below your historical $16M-$18M run rate?
HealthCare Royalty Amendment Strategy
The reduction of the change-of-control payment from $750M to $150M is a massive structural change. Were you receiving feedback from potential partners or acquirers that the previous penalty was a non-starter for strategic discussions?
Compendia Listing Requirements
For the LOTIS-7 compendia inclusion strategy, what specific duration of response or maturity of data do you believe the NCCN guidelines will require before granting a listing, given the novelty of the bispecific combination?